NEW YORK, March 21, 2014 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced that trading of Versartis, Inc. (Nasdaq:VSAR), a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of endocrine disorders, commenced on The NASDAQ Stock Market® on March 21, 2014.
"Versartis is an innovative company dedicated to improving the treatment of growth hormone deficiency," said Bruce Aust, Executive Vice President, Corporate Client Group, NASDAQ OMX. "We are pleased to welcome Versartis to the NASDAQ family."
Versartis, Inc. is initially developing VRS-317, a novel, long-acting form of recombinant human growth hormone, for the treatment of pediatric growth hormone deficiency (GHD). The company is currently completing a Phase 2a clinical trial of VRS-317 in children with GHD. VRS-317 is a fusion protein consisting of rhGH and a proprietary half-life extension technology known as XTEN, which is in-licensed from Amunix Operating, Inc. Amunix has granted Versartis an exclusive license under its patents and know-how related to the XTEN technology to develop and commercialize up to four licensed products, including VRS-317.
By listing with NASDAQ®, Versartis, Inc. joins some of the world's largest and most revolutionary health care companies. NASDAQ has been the exchange of choice to 100 percent of biotech companies that have listed on the U.S. markets year-to-date in 2014.
Cautionary Note Regarding Forward-Looking Statements
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding NASDAQ-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
About The NASDAQ OMX Group
NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 80 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,200 listed companies with a market value of over $8 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.
CONTACT: MEDIA RELATIONS CONTACT: Christine Barna (646) 441-5310 Christine.Barna@nasdaqomx.com